---
document_datetime: 2025-12-09 23:15:38
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tryngolza.html
document_name: tryngolza.html
version: success
processing_time: 0.1064366
conversion_datetime: 2025-12-28 14:26:44.568092
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tryngolza

[RSS](/en/individual-human-medicine.xml/263610)

##### Authorised

This medicine is authorised for use in the European Union

olezarsen Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tryngolza](#news-on)
- [More information on Tryngolza](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tryngolza is a medicine used together with diet to treat adults with familial chylomicronaemia syndrome (FCS), a genetic condition that gives rise to high levels of fats called triglycerides in the blood. The excess fat builds up in various parts of the body and leads to symptoms including abdominal pain (belly ache), deposits of fat under the skin and pancreatitis (inflammation of the pancreas). Tryngolza is used to treat FCS that has been confirmed by genetic testing.

FCS is rare, and Tryngolza was designated an 'orphan medicine' (a medicine used in rare diseases) on 21 August 2024. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2973) .

Tryngolza contains the active substance olezarsen.

Expand section

Collapse section

## How is Tryngolza used?

Tryngolza can only be obtained with a prescription and is available as a solution for injection in prefilled pens. It is injected once a month under the skin in the abdomen (belly), the front of the thigh or the back of the upper arm. Patients or their carers can inject Tryngolza themselves once they have been trained.

For more information about using Tryngolza, see the package leaflet or contact your doctor or pharmacist.

## How does Tryngolza work?

The active substance in Tryngolza, olezarsen, is an 'antisense oligonucleotide,' a very short piece of synthetic (man-made) RNA (a type of genetic material). It has been designed to block the production of a protein called apolipoprotein C-III (apoC-III), which slows down the breakdown of fats. By blocking the production of this protein, the medicine reduces the level of triglycerides in the blood and, as a result, fat accumulation in the body.

## What benefits of Tryngolza have been shown in studies?

Tryngolza was shown to be effective at reducing triglycerides levels in the blood in one main study involving 66 adults with FCS. All patients in the study were on a controlled diet in addition to receiving Tryngolza or placebo (a dummy treatment).

After 6 months of treatment, patients receiving Tryngolza had an average reduction in the blood level of triglycerides of 32%, compared with an average increase of 12% in patients given placebo. This effect was maintained and improved after one year of treatment; the study also showed that there were much fewer cases of acute pancreatitis in patients using Tryngolza compared with those using placebo.

## What are the risks associated with Tryngolza?

For the full list of side effects and restrictions with Tryngolza, see the package leaflet.

The most common side effects with Tryngolza (which may affect more than 1 in 10 people) include erythema (reddening of the skin) at the injection site, headache, joint pain and vomiting.

## Why is Tryngolza authorised in the EU?

Tryngolza was shown to reduce blood levels of triglycerides and lower the risk of acute pancreatitis in patients with FCS. The safety of the medicine was considered acceptable, especially the fact that Tryngolza does not seem to affect blood levels of platelets (components that help the blood to clot). Its monthly dosing schedule and improved safety were also considered of benefit to patients with FCS. The European Medicines Agency therefore decided that Tryngolza's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Tryngolza?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tryngolza have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tryngolza are continuously monitored. Suspected side effects reported with Tryngolza are carefully evaluated and any necessary action taken to protect patients.

## Other information about Tryngolza

Tryngolza received a marketing authorisation valid throughout the EU on 17 September 2025.

Tryngolza : EPAR - Medicine overview

Reference Number: EMA/258552/2025

English (EN) (111.12 KB - PDF)

**First published:** 17/10/2025

[View](/en/documents/overview/tryngolza-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-609)

български (BG) (136.12 KB - PDF)

**First published:**

17/10/2025

[View](/bg/documents/overview/tryngolza-epar-medicine-overview_bg.pdf)

español (ES) (118.38 KB - PDF)

**First published:**

17/10/2025

[View](/es/documents/overview/tryngolza-epar-medicine-overview_es.pdf)

čeština (CS) (139.6 KB - PDF)

**First published:**

17/10/2025

[View](/cs/documents/overview/tryngolza-epar-medicine-overview_cs.pdf)

dansk (DA) (118.33 KB - PDF)

**First published:**

17/10/2025

[View](/da/documents/overview/tryngolza-epar-medicine-overview_da.pdf)

Deutsch (DE) (121.26 KB - PDF)

**First published:**

17/10/2025

[View](/de/documents/overview/tryngolza-epar-medicine-overview_de.pdf)

eesti keel (ET) (115.83 KB - PDF)

**First published:**

17/10/2025

[View](/et/documents/overview/tryngolza-epar-medicine-overview_et.pdf)

ελληνικά (EL) (140.92 KB - PDF)

**First published:**

17/10/2025

[View](/el/documents/overview/tryngolza-epar-medicine-overview_el.pdf)

français (FR) (119.11 KB - PDF)

**First published:**

17/10/2025

[View](/fr/documents/overview/tryngolza-epar-medicine-overview_fr.pdf)

hrvatski (HR) (139.35 KB - PDF)

**First published:**

17/10/2025

[View](/hr/documents/overview/tryngolza-epar-medicine-overview_hr.pdf)

italiano (IT) (117.72 KB - PDF)

**First published:**

17/10/2025

[View](/it/documents/overview/tryngolza-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (146.19 KB - PDF)

**First published:**

17/10/2025

[View](/lv/documents/overview/tryngolza-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (138.46 KB - PDF)

**First published:**

17/10/2025

[View](/lt/documents/overview/tryngolza-epar-medicine-overview_lt.pdf)

magyar (HU) (137.47 KB - PDF)

**First published:**

17/10/2025

[View](/hu/documents/overview/tryngolza-epar-medicine-overview_hu.pdf)

Malti (MT) (141.2 KB - PDF)

**First published:**

17/10/2025

[View](/mt/documents/overview/tryngolza-epar-medicine-overview_mt.pdf)

Nederlands (NL) (118.46 KB - PDF)

**First published:**

17/10/2025

[View](/nl/documents/overview/tryngolza-epar-medicine-overview_nl.pdf)

polski (PL) (143.64 KB - PDF)

**First published:**

17/10/2025

[View](/pl/documents/overview/tryngolza-epar-medicine-overview_pl.pdf)

português (PT) (119.03 KB - PDF)

**First published:**

17/10/2025

[View](/pt/documents/overview/tryngolza-epar-medicine-overview_pt.pdf)

română (RO) (136.93 KB - PDF)

**First published:**

17/10/2025

[View](/ro/documents/overview/tryngolza-epar-medicine-overview_ro.pdf)

slovenčina (SK) (140.22 KB - PDF)

**First published:**

17/10/2025

[View](/sk/documents/overview/tryngolza-epar-medicine-overview_sk.pdf)

slovenščina (SL) (138.92 KB - PDF)

**First published:**

17/10/2025

[View](/sl/documents/overview/tryngolza-epar-medicine-overview_sl.pdf)

Suomi (FI) (115.74 KB - PDF)

**First published:**

17/10/2025

[View](/fi/documents/overview/tryngolza-epar-medicine-overview_fi.pdf)

svenska (SV) (116.45 KB - PDF)

**First published:**

17/10/2025

[View](/sv/documents/overview/tryngolza-epar-medicine-overview_sv.pdf)

Tryngolza : EPAR - Risk management plan

English (EN) (1.67 MB - PDF)

**First published:** 17/10/2025

[View](/en/documents/rmp/tryngolza-epar-risk-management-plan_en.pdf)

## Product information

Tryngolza : EPAR - Product information

English (EN) (429.25 KB - PDF)

**First published:** 17/10/2025

**Last updated:** 03/12/2025

[View](/en/documents/product-information/tryngolza-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-147)

български (BG) (630.09 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/bg/documents/product-information/tryngolza-epar-product-information_bg.pdf)

español (ES) (445.35 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/es/documents/product-information/tryngolza-epar-product-information_es.pdf)

čeština (CS) (658.88 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/cs/documents/product-information/tryngolza-epar-product-information_cs.pdf)

dansk (DA) (504.88 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/da/documents/product-information/tryngolza-epar-product-information_da.pdf)

Deutsch (DE) (505.65 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/de/documents/product-information/tryngolza-epar-product-information_de.pdf)

eesti keel (ET) (549.1 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/et/documents/product-information/tryngolza-epar-product-information_et.pdf)

ελληνικά (EL) (622.73 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/el/documents/product-information/tryngolza-epar-product-information_el.pdf)

français (FR) (602.98 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/fr/documents/product-information/tryngolza-epar-product-information_fr.pdf)

hrvatski (HR) (618.69 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/hr/documents/product-information/tryngolza-epar-product-information_hr.pdf)

íslenska (IS) (487.27 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/is/documents/product-information/tryngolza-epar-product-information_is.pdf)

italiano (IT) (651.24 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/it/documents/product-information/tryngolza-epar-product-information_it.pdf)

latviešu valoda (LV) (605.92 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/lv/documents/product-information/tryngolza-epar-product-information_lv.pdf)

lietuvių kalba (LT) (626.42 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/lt/documents/product-information/tryngolza-epar-product-information_lt.pdf)

magyar (HU) (610.25 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/hu/documents/product-information/tryngolza-epar-product-information_hu.pdf)

Malti (MT) (681.66 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/mt/documents/product-information/tryngolza-epar-product-information_mt.pdf)

Nederlands (NL) (505.59 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/nl/documents/product-information/tryngolza-epar-product-information_nl.pdf)

norsk (NO) (531.19 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/no/documents/product-information/tryngolza-epar-product-information_no.pdf)

polski (PL) (638.45 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/pl/documents/product-information/tryngolza-epar-product-information_pl.pdf)

português (PT) (500.37 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/pt/documents/product-information/tryngolza-epar-product-information_pt.pdf)

română (RO) (626.63 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/ro/documents/product-information/tryngolza-epar-product-information_ro.pdf)

slovenčina (SK) (654.97 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/sk/documents/product-information/tryngolza-epar-product-information_sk.pdf)

slovenščina (SL) (608.78 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/sl/documents/product-information/tryngolza-epar-product-information_sl.pdf)

Suomi (FI) (529.66 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/fi/documents/product-information/tryngolza-epar-product-information_fi.pdf)

svenska (SV) (517.08 KB - PDF)

**First published:**

17/10/2025

**Last updated:**

03/12/2025

[View](/sv/documents/product-information/tryngolza-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000314777 01/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tryngolza : EPAR - All authorised presentations

English (EN) (38.62 KB - PDF)

**First published:** 17/10/2025

[View](/en/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-329)

български (BG) (57.4 KB - PDF)

**First published:**

17/10/2025

[View](/bg/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_bg.pdf)

español (ES) (39.03 KB - PDF)

**First published:**

17/10/2025

[View](/es/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_es.pdf)

čeština (CS) (55.87 KB - PDF)

**First published:**

17/10/2025

[View](/cs/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (42.76 KB - PDF)

**First published:**

17/10/2025

[View](/da/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (40.68 KB - PDF)

**First published:**

17/10/2025

[View](/de/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (40.11 KB - PDF)

**First published:**

17/10/2025

[View](/et/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (57.03 KB - PDF)

**First published:**

17/10/2025

[View](/el/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_el.pdf)

français (FR) (40.83 KB - PDF)

**First published:**

17/10/2025

[View](/fr/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (48.34 KB - PDF)

**First published:**

17/10/2025

[View](/hr/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (38.83 KB - PDF)

**First published:**

17/10/2025

[View](/is/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_is.pdf)

italiano (IT) (37.43 KB - PDF)

**First published:**

17/10/2025

[View](/it/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (58.23 KB - PDF)

**First published:**

17/10/2025

[View](/lv/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (57.56 KB - PDF)

**First published:**

17/10/2025

[View](/lt/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (58.78 KB - PDF)

**First published:**

17/10/2025

[View](/hu/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (61.17 KB - PDF)

**First published:**

17/10/2025

[View](/mt/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (40.42 KB - PDF)

**First published:**

17/10/2025

[View](/nl/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (40.46 KB - PDF)

**First published:**

17/10/2025

[View](/no/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_no.pdf)

polski (PL) (59.91 KB - PDF)

**First published:**

17/10/2025

[View](/pl/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_pl.pdf)

português (PT) (39.29 KB - PDF)

**First published:**

17/10/2025

[View](/pt/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_pt.pdf)

română (RO) (57.21 KB - PDF)

**First published:**

17/10/2025

[View](/ro/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (57.16 KB - PDF)

**First published:**

17/10/2025

[View](/sk/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (46 KB - PDF)

**First published:**

17/10/2025

[View](/sl/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (44.92 KB - PDF)

**First published:**

17/10/2025

[View](/fi/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (37.26 KB - PDF)

**First published:**

17/10/2025

[View](/sv/documents/all-authorised-presentations/tryngolza-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tryngolza Active substance olezarsen sodium International non-proprietary name (INN) or common name olezarsen Therapeutic area (MeSH) Hyperlipoproteinemia Type I Anatomical therapeutic chemical (ATC) code C10AX

### Pharmacotherapeutic group

Lipid modifying agents

### Therapeutic indication

Tryngolza is indicated as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS).

## Authorisation details

EMA product number EMEA/H/C/006477

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Swedish Orphan Biovitrum AB (publ)

SE-112 76 Stockholm

Opinion adopted 24/07/2025 Marketing authorisation issued 17/09/2025 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tryngolza : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (235.11 KB - PDF)

**First published:** 03/12/2025

[View](/en/documents/procedural-steps-after/tryngolza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Tryngolza - Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-2329606

English (EN) (279.16 KB - PDF)

**First published:** 17/10/2025

[View](/en/documents/orphan-maintenance-report/tryngolza-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Tryngolza : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/216788/2025

English (EN) (6.17 MB - PDF)

**First published:** 17/10/2025

[View](/en/documents/assessment-report/tryngolza-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tryngolza

Adopted

Reference Number: EMA/CHMP/225521/2025

English (EN) (121.14 KB - PDF)

**First published:** 25/07/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tryngolza_en.pdf)

#### News on Tryngolza

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-july-2025) 25/07/2025

#### More information on Tryngolza

- [EU/3/24/2973 - orphan designation for treatment of familial chylomicronaemia syndrome](/en/medicines/human/orphan-designations/eu-3-24-2973)

**This page was last updated on** 03/12/2025

## Share this page

[Back to top](#main-content)